<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01508221</url>
  </required_header>
  <id_info>
    <org_study_id>BTC-W1</org_study_id>
    <nct_id>NCT01508221</nct_id>
  </id_info>
  <brief_title>Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis</brief_title>
  <official_title>A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of Trental and Vitamin E can help
      reduce the incidence of radiation necrosis (a lesion that usually occurs at the original
      tumor site) after radiosurgery.  These two drugs are commonly used to treat radiation
      necrosis when it occurs but the hope is that these drugs can be used to prevent radiation
      necrosis from ever occurring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment phase of the study is 6 months. Study procedures will be conducted such as:
      history, physical and neurological exam, pregnancy testing (for women of child bearing age)
      and a Brain MRI.   Follow-up appointments will be every 3 months for 1 year at which time,
      your participation in the study will be concluded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of symptomatic radiation necrosis</measure>
    <time_frame>average 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>Trental + Vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trental</intervention_name>
    <description>400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months</description>
    <arm_group_label>Trental + Vitamin E</arm_group_label>
    <other_name>Pentoxifylline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months</description>
    <arm_group_label>Trental + Vitamin E</arm_group_label>
    <other_name>Vitamin E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor

          -  Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation
             or by clinical confirmation by the treating physician based on MR imaging
             characteristics in the setting of a known history of cancer

          -  Age &gt; 18 years

          -  Partial or total resection of a metastatic tumor are eligible

        Exclusion Criteria:

          -  Known sensitivity to vitamin E or Trental

          -  Recent intracranial bleed or retinal hemorrhage

          -  Treatment with a non-approved or investigational drug within 30 days before day 1 of
             study treatment

          -  History of Avastin treatment

          -  Anticipated need for treatment with Avastin

          -  History of bleeding disorder

          -  History of liver disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Warnick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UC Cancer Institute</last_name>
    <phone>513-584-7698</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UC Cancer Institute</last_name>
      <phone>513-584-7698</phone>
    </contact>
    <investigator>
      <last_name>Ronald Warnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Ronald Warnick</investigator_full_name>
    <investigator_title>Medical Director, University of Cincinnati Brain Tumor Center</investigator_title>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
